Axonics provides update on inter partes review proceedings

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that the patent trial and appeal board (ptab) of the u.s. patent and trademark office has issued written decisions on two medtronic patents that axonics is contesting. the ptab issued its decision with respect to patent nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). medtronic has asserted these patents, which expired in 2021 and 2022, against axonics' proprietary tined lead design. today, the pt.
AXNX Ratings Summary
AXNX Quant Ranking